�Bavarian Nordic's US subsidiary company, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic testament jointly develop new immunotherapies for the treatment of prostate malignant neoplastic disease. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively licence intellectual belongings that results from this collaboration.
Bavarian Nordic will in the future explore opportunities for extending this collaboration to further rise its cancer the Crab projects. By combining Bavarian Nordic's expertise within genus Cancer vaccine exploitation with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration volition result in new and innovative solutions to a disease area with high school unmet medical needs as well as expand and accelerate Bavarian Nordic's malignant neoplastic disease activities.
Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to noetic property rights covering a prostate cancer vaccine product candidate in late form II clinical development. Data from key clinical studies with this vaccine nominee are currently being evaluated. Later in 2008 the company testament inform the market about how this development project will give birth a future in the pipeline of Bavarian Nordic.
About the NCIThe National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's leading cancer research organization.
- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.
- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.
- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the antitumour drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.
The collaboration with the NCI does not change Bavarian Nordic's previously announced fiscal guidance for 2008.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented:
"I am very happy to see that we are consolidating our inviolable relationships within the US. The NCI relationship opens up for us new and exciting opportunities inside the field of cancer and we are proud to bring together forces with one of the nearly prestigious and well-established cancer research organisations in the world. In the collaboration with NCI Bavarian Nordic benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organization. This will truly fortify cancer as a strategical focus country in days to come, in pipeline with our outlined strategy."
About Bavarian NordicBavarian Nordic A/S is a leading industrial biotechnology company development and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focussed in triad areas: biological defence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented applied science MVA-BN� is one of the world's safest, multi-valued vaccine vectors. Bavarian Nordic has on-going contracts with the US government for the late-stage development and procurement of the company's third-generation variola vaccine, IMVAMUNE�.
Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbolisation BAVA.
Bavarian Nordic
More information
